Tags : PAOLA-1

AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1

Shots: The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. as a 1L maintenance therapy for newly diagnosed advanced FIGO Stage III-IV high grade serous or endometroid ovarian, fallopian tube, peritoneal cancer women prior treated with platinum-based CT + bevacizumab The P-III PAOLA-1 study resulted in meeting its 1EPs in […]Read More